Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 835.07M |
| Revenue (ttm) | 1.64B |
| Net Income (ttm) | -516.47M |
| Shares Out | 77.83M |
| EPS (ttm) | -6.74 |
| PE Ratio | n/a |
| Forward PE | 4.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 790,846 |
| Open | 10.76 |
| Previous Close | 10.69 |
| Day's Range | 10.44 - 10.86 |
| 52-Week Range | 8.70 - 17.54 |
| Beta | 1.07 |
| Analysts | Hold |
| Price Target | 14.33 (+33.55%) |
| Earnings Date | May 5, 2026 |
About IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after... [Read more]
Financial Performance
In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $14.33, which is an increase of 33.55% from the latest price.
News
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial res...
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April Results to be featured at Functional Diabetic Limb Salvage...
Integra LifeSciences Holdings Earnings Call Transcript: Q4 2025
Q4 2025 revenue and EPS exceeded guidance midpoints, despite year-over-year declines due to supply and remediation headwinds. 2026 guidance anticipates modest growth, improved free cash flow, and continued operational transformation, with tariff impacts and product relaunches as key variables.
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 20...
Integra LifeSciences Announces Key Executive Leadership Appointments
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Ela...
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025...
Integra LifeSciences Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Leading positions in neurosurgery and tissue technologies support a $1.6B business, now undergoing a major transformation focused on quality, supply chain, and innovation. Product relaunches, margin expansion, and favorable reimbursement changes are expected to drive growth and improved leverage in 2026.
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Holdings Transcript: Citi Annual Global Healthcare Conference 2025
Leadership is driving operational improvements, portfolio realignment, and supply chain optimization, with a focus on quality systems and financial discipline. Growth is targeted in tissue technology and IBBR, while margin expansion and leverage reduction remain top priorities through 2026.
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid S...
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearanc...
Integra LifeSciences Holdings Earnings Call Transcript: Q3 2025
Q3 revenue grew 5% organically year-over-year but missed guidance due to supply chain and private label headwinds, while adjusted EPS exceeded expectations. PriMatrix and Durepair relaunched ahead of schedule, and 2025 guidance was revised lower, with modest growth expected in 2026.
Integra LifeSciences Reports Third Quarter 2025 Financial Results
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third...
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial resu...
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president an...
Integra LifeSciences Holdings Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Leadership is driving compliance, operational excellence, and financial discipline, with a focus on culture and growth. Portfolio prioritization and cost initiatives are underway, while regulatory remediation and PMA progress support future expansion. Growth is expected to accelerate in 2026 as supply and operational improvements take hold.
Integra LifeSciences Holdings Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Management outlined a focus on operational improvements, margin expansion, and supply stabilization, with a $25–$30 million savings target by 2026. Growth will be driven by product reintroduction, international expansion, and innovation, while capital allocation remains focused on debt reduction.
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Holdings Earnings Call Transcript: Q2 2025
Q2 revenue exceeded guidance at $415.6M, but was down slightly year-over-year due to ship holds. Adjusted EPS was $0.45, with a $511M non-cash goodwill impairment. Full-year guidance was updated, with no new ship holds expected and cost savings initiatives underway.
Integra LifeSciences Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the secon...
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial res...
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first pa...
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Integra LifeSciences Holdings Corp. and Encourages Long-Term Investors to Contact the Firm – IART
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Integra LifeSciences Holdings Corp. (NASDAQ:...